People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Pharmaceuticals, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Design Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $170.5M | $3.7B | 2021 |
| Anaptysbio Inc | — | Pharmaceuticals | Series C | $50.8M | $1.4B | 2015 |
| Trius Therapeutics Inc | — | Biotechnology | Series B | $49.3M | $1.2B | 2009 |
| WinPro Parking,LLC | — | Other | Pre-Seed | $400K | $9.2M | 2014 |
John Schmid at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Schmid on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Topper | 1 | 12 |
| Heath Lukatch | 1 | 10 |
| Risa Stack | 1 | 9 |
| Tiba Aynechi | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| David Kabakoff | 1 | 7 |
| Carol Gallagher | 1 | 6 |
| Robert Hoffman | 1 | 5 |
| John Finn | 1 | 5 |
| James N. Topper | 1 | 5 |
| Nina S. Kjellson | 1 | 4 |
| Theodore R. Schroeder | 1 | 4 |
| Kevin Kinsella | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| Paul Truex | 1 | 3 |
| J Leighton Read | 1 | 2 |
| Nina G. Kjellson | 1 | 2 |
| Carol N. Gallagher | 1 | 2 |
| Paul F. Truex | 1 | 2 |
| Pratik Shah, Ph.D. | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.